Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers.
Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.
Location: United States, Virginia, Charlottesville
Employees: 11-50
Phone: +1 434-297-1000
Total raised: $160M
Founded date: 1996
Investors 4
| Date | Name | Website |
| - | Western Te... | westerntec... |
| - | PBM Capita... | pbmcap.com |
| - | RA Capital... | racap.com |
| - | K2 HealthV... | k2hv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.07.2021 | - | $160M | - |
Mentions in press and media 8
| Date | Title | Description | Source |
| 12.03.2024 | Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS... | CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS)... | einpresswi... |
| 11.03.2024 | Neurological Biomarkers Market 2024 Global Analysis: Insight... | Neurological Biomarkers Market Neurological biomarkers are detectable substances majorly found in th... | einpresswi... |
| 20.02.2024 | Health | Inside the plan to diagnose Alzheimer’s in people w... | Melody Petersen | Los Angeles Times (TNS) In a darkened Amsterdam conference hall this summer, a pan... | dailycamer... |
| 13.11.2023 | Acumen Pharmaceuticals Secures $50.0 Million Credit Facility... | Provides additional capital to support development of a subcutaneous formulation of ACU193 and gener... | einpresswi... |
| 13.11.2023 | Acumen Pharmaceuticals Secures $50.0 Million Credit Facility... | - | globenewsw... |
| 01.07.2021 | All in on amyloid, Acumen Pharma’s IPO raises $160M for Alzh... | Acumen Pharmaceuticals is developing an Alzheimer’s disease drug that it believes offers advantages ... | medcitynew... |
| 23.05.2013 | After a restructure and an axed Merck deal, Acumen gains $20... | They found that soluble oligomers they called amyloid beta-derived diffusible ligands, or ADDLs, wer... | medcitynew... |
| - | After a restructure and an axed Merck deal, Acumen gains $20... | It’s been 17 years in the making, but Acumen Pharmaceuticals hasn’t given up hope for its approach t... | medcitynew... |